Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. cut its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 21.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,254 shares of the company’s stock after selling 1,412 shares during the period. Lecap Asset Management Ltd.’s holdings in Inspire Medical Systems were worth $974,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. True Wealth Design LLC purchased a new position in Inspire Medical Systems during the third quarter valued at $30,000. Farther Finance Advisors LLC raised its position in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after purchasing an additional 139 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after purchasing an additional 151 shares during the last quarter. Signaturefd LLC lifted its stake in Inspire Medical Systems by 45.9% in the 3rd quarter. Signaturefd LLC now owns 270 shares of the company’s stock valued at $57,000 after buying an additional 85 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Inspire Medical Systems by 37.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Stifel Nicolaus decreased their target price on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research report on Tuesday, January 21st. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $220.00 to $255.00 in a research note on Wednesday, November 20th. Robert W. Baird increased their target price on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Finally, Wells Fargo & Company upped their price objective on shares of Inspire Medical Systems from $187.00 to $198.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $231.45.

Inspire Medical Systems Stock Performance

INSP opened at $182.00 on Friday. The stock has a market capitalization of $5.45 billion, a PE ratio of 170.10 and a beta of 1.32. Inspire Medical Systems, Inc. has a one year low of $123.00 and a one year high of $257.40. The business’s 50 day moving average price is $189.94 and its 200 day moving average price is $189.68.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.